NCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown
Clinical Trials
309 trialsNCT03576378 2024-02-26
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Unknown
NCT03068624 2024-01-25
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT06182735 2023-12-27
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Fudan University
Phase 1 Unknown
NCT06160362 2023-12-07
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Phase NA Unknown
NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05732948 2023-11-29
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03600649 2023-11-21
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Phase 1 Unknown
NCT03926091 2023-11-14
CLOVER
Fudan University
Phase 3 Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT05266196 2023-08-01
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Salarius Pharmaceuticals, LLC
Phase 1/2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT01374841 2023-06-28
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
European Institute of Oncology
Phase 2 Unknown
NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
NCT05914753 2023-06-22
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Zhejiang Provincial People's Hospital
Phase NA Unknown
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT05872412 2023-05-25
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2 Unknown
NCT04433156 2023-05-18
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05798546 2023-04-04
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
Phase 1 Unknown
NCT05777369 2023-03-21
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT03412643 2023-03-06
FB-12
NSABP Foundation Inc
Phase 2 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04706936 2023-02-06
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT03252600 2023-01-25
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Phase 2 Unknown
NCT05681728 2023-01-12
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT05654077 2022-12-19
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT05616468 2022-12-15
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05640713 2022-12-07
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Phase 1 Unknown
NCT01946373 2022-10-04
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
Phase 1 Unknown
NCT03336073 2022-09-07
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation
Phase 2 Unknown
NCT05515185 2022-08-25
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
Phase EARLY_PHASE1 Unknown
NCT05491694 2022-08-08
HIFU
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05483439 2022-08-05
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Phase 2 Unknown
NCT03692663 2022-08-01
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02562365 2022-07-27
ACTS
Fudan University
Phase 2 Unknown
NCT05122221 2022-06-28
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Unknown
NCT05400993 2022-06-06
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Shengjing Hospital
Phase 2 Unknown
NCT02639650 2022-06-03
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown